第48届圣安东尼奥乳腺癌研讨会（SABCS 2025）将于当地时间2025年12月9-12日在美国得克萨斯州圣安东尼奥Henry B.Gonzalez Convention Center举行。作为乳腺癌领域的顶级盛会，SABCS聚焦乳腺癌生物学、病因、预防、诊断及治疗前沿，促进临床、转化与基础研究的深度融合，为全球科研人员提供交流协作与专业成长的平台。肿瘤瞭望-乳腺时讯特对会议第三天（12月11日）内容进行梳理，涵盖全体大会、Mini口头报告、海报聚焦专场、海报展示、前沿进展专场、教育专场及特殊专场等，并将全体大会2（General Session 2）及Mini口头报告（Rapid Fire 7和Rapid Fire 4）题目进行整理，以便读者快速了解会议动态，敬请关注后续详细报道！
编者按：第48届圣安东尼奥乳腺癌研讨会（SABCS 2025）将于当地时间2025年12月9-12日在美国得克萨斯州圣安东尼奥Henry B.Gonzalez Convention Center举行。作为乳腺癌领域的顶级盛会，SABCS聚焦乳腺癌生物学、病因、预防、诊断及治疗前沿，促进临床、转化与基础研究的深度融合，为全球科研人员提供交流协作与专业成长的平台。肿瘤瞭望-乳腺时讯特对会议第三天（12月11日）内容进行梳理，涵盖全体大会、Mini口头报告、海报聚焦专场、海报展示、前沿进展专场、教育专场及特殊专场等，并将全体大会2（General Session 2）及Mini口头报告（Rapid Fire 7和Rapid Fire 4）题目进行整理，以便读者快速了解会议动态，敬请关注后续详细报道！
五场海报聚焦专场：1、海报聚焦5：乳腺癌液体生物标志物——推动精准医疗新实践；2、海报聚焦6：新辅助治疗疗效预测与预后评估工具前沿；3、海报聚焦7：早期三阴性乳腺癌——生物标志物与创新治疗策略；4、海报聚焦8：超越量表——肥胖与GLP-1疗法在乳腺癌中的探索；5、海报聚焦9：乳腺小叶癌专题研讨。
一场大会特邀讲座：合作促进进步。
一场全体大会专场：全体大会2。
一场案例讨论：分子肿瘤专家会诊
一场颁奖讲座：AACR乳腺癌研究杰出讲座奖
两场海报展示：1、Poster Session 3；2、Poster Session 4。
一场辩论：多学科治疗中的腋窝管理
两场Mini口头报告：1、Rapid Fire 7；2、Rapid Fire 4。
一场前沿进展专场——最新进展2：靶向非T细胞微环境
五场教育专场：1、教育专场11：如何治疗三阴性乳腺癌——“三阴”不再意味着治疗困境；2、教育专场12：乳腺癌前沿探索——靶向治疗耐药性的突破策略；3、教育专场13：优化乳腺癌患者心脏预后——心血管管理新篇章；4、教育专场14：年轻女性乳腺癌诊疗精要——发病机制、时机与临床对策；5、教育专场15：人工智能赋能乳腺癌诊疗——实现临床实践新跨越。
一场特殊专场——FDA会议：2025年HR+转移性乳腺癌进展、监管机构批准和未来试验
专场：General Session 2
时间：12月11日9:00 AM–12:00 PM CST
地点：Hall 1
摘要号：GS2-01
More versus less invasive axillary surgical staging procedures in breast cancer patients converting from a clinically node-positive to a clinically node-negative stage through neoadjuvant chemotherapy–primary endpoint analysis of the international prospective multicenter AXSANA/EUBREAST 3(R)study
在通过新辅助化疗从临床淋巴结阳性转为临床淋巴结阴性的乳腺癌患者中，腋窝手术分期术式范围对比（扩大与缩小）——国际前瞻性多中心AXSANA/EUBREAST-3研究的主要终点分析
讲者：Thorsten Kühn，Die Filderklinik gGmbH/University of Ulm，Ulm，Germany
摘要号：GS2-02
Axillary surgery in breast cancer patients with one to three sentinel node macrometastases and breast-conserving therapy:Secondary results of the INSEMA trial
针对存在1-3个前哨淋巴结宏转移且接受保乳治疗的乳腺癌患者，腋窝手术的疗效：INSEMA试验的次要结果分析
讲者：Toralf Reimer，University of Rostock，Rostock，Germany
摘要号：GS2-03
Insights of applied radiotherapy among patients undergoing breast-conserving surgery with or without axillary sentinel lymph node biopsy:secondary results from the INSEMA trial
接受保乳手术（联合或不联合腋窝前哨淋巴结活检）患者中放疗应用情况的深入分析：INSEMA试验的次要结果
讲者：Guido Hildebrandt，University Medicine Rostock，Rostock，Germany
摘要号：GS2-04
Heating up cold tumors:single-cell mapping of immune and adenosine pathway reprogramming in luminal B breast cancer(Neo-CheckRay trial)
加热“冷肿瘤”：luminal B型乳腺癌中免疫与腺苷通路重编程的单细胞图谱绘制（Neo-CheckRay试验）
讲者：Marcela Carausu，Institut Jules Bordet，Brussels，Belgium
摘要号：GS2-05
Primary Results from the HR+/HER2-Cohort of TBCRC-053(P-RAD):A Randomized Trial of No，Low，or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive，HER2-Negative Breast Cancer
TBCRC-053（P-RAD）研究中HR+/HER2-队列的初步结果：一项针对淋巴结阳性、HER2阴性乳腺癌，比较术前无辐射剂量、低剂量或高剂量放疗联合帕博利珠单抗（Pembrolizumab）及化疗的随机试验
讲者：Gaorav Gupta，University of North Carolina at Chapel Hill，Chapel Hill，NC
摘要号：GS2-07
Effect of Preoperative Breast MRI Staging on Local Regional Recurrence(LRR)in Early Stage Breast cancer:Alliance A011104/ACRIN 6694
术前乳腺磁共振成像（MRI）分期对早期乳腺癌局部区域复发（LRR）的影响：Alliance A011104/ACRIN 6694研究
讲者：Isabelle Bedrosian，University of Texas MD Anderson Cancer Center，Houston，TX
摘要号：GS2-09
The single-arm confirmatory trial of tamoxifen alone without surgery for low-risk DCIS of the breast with ER-positive HER2-negative(LORETTA trial:JCOG1505)
针对ER+/HER2-的低风险乳腺导管原位癌（DCIS），仅采用他莫昔芬单药治疗且不施行手术的单臂验证性试验（LORETTA研究：JCOG1505）
讲者：Hiroji Iwata，Nagoya City University Graduate School of Medical Sciences，Nagoya，Japan
摘要号：GS2-11
Omission of sentinel lymph node biopsy in clinically T1-2 node-negative breast cancer patients treated with breast-conserving therapy:results of the Dutch BOOG 2013-08 randomized controlled trial after a median follow-up of 5 years
对接受保乳治疗的临床T1-2期且淋巴结阴性的乳腺癌患者省略前哨淋巴结活检术：荷兰BOOG 2013-08随机对照试验中位随访5年后的结果
讲者：M.L.Smidt，Maastricht University Medical Center+，Maastricht，Netherlands
摘要号：GS2-12
Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast(BIG 3-07/TROG 07.01):final 10-year analysis of a randomised，factorial，multicentre，open-label，phase 3 study
非低风险乳腺导管原位癌的放射剂量与分次照射方案（BIG 3-07/TROG 07.01研究）：一项随机、析因、多中心、开放标签的Ⅲ期研究的最终10年分析
讲者：Boon H Chua，University of New South Wales，Sydney，Australia
专场：Rapid Fire 7
时间：12月11日1:00 PM–2:00 PM CST
地点：Stars at Night 1-2
摘要号：RF7-01
Elacestrant in combination with everolimus or abemaciclib in patients with ER+/HER2-locally advanced or metastatic breast cancer(mBC):phase 2 results from ELEVATE，an open-label，umbrella study
Elacestrant联合依维莫司或阿贝西利治疗ER+/HER2-局部晚期或转移性乳腺癌（mBC）患者：ELEVATE（一项开放标签、伞形研究）的2期结果
讲者：Hope Rugo，City of Hope Duarte Cancer Center，Duarte，CA
摘要号：RF7-02
Alpelisib plus fulvestrant for PIK3CA-mutated，HR-positive，HER2-negative advanced breast cancer after a CDK4/6 inhibitor(EPIK-B5):Phase III，randomized，double-blind，placebo-controlled，multicenter study
Alpelisib联合氟维司群治疗CDK4/6抑制剂（EPIK-B5）经治后的PIK3CA突变、HR+/HER2-晚期乳腺癌：III期、随机、双盲、安慰剂对照、多中心研究
讲者：Michelino De Laurentiis，Department of Breast and Thoracic Oncology，National Cancer Institute“Fondazione Pascale”，Naples，Italy
摘要号：RF7-03
Updated results and an exploratory analysis of ESR1m circulating tumor DNA(ctDNA)dynamics from SERENA-6，a phase 3 trial of camizestrant(CAMI)+CDK4/6 inhibitor(CDK4/6i)for emergent ESR1 mutations(ESR1m)during first-line(1L)endocrine-based therapy and ahead of disease progression in patients(pts)with HR+/HER2-advanced breast cancer(ABC)
SERENA-6研究更新结果及ESR1突变ctDNA的动态探索性分析：SERENA-6是一项关于camizestrant(CAMI)+CDK4/6抑制剂用于HR+/HER2-晚期乳腺癌（ABC）患者在一线（1L）内分泌治疗期间发生ESR1m突变且在疾病进展之前（ESR1m）的3期研究
讲者：François-Clément Bidard，Institut Curie，Paris，France
摘要号：RF7-04
Gedatolisib，a multi-target PI3K/AKT/mTOR(PAM)inhibitor，plus fulvestrant with or without palbociclib for second-line(2L)treatment of patients with HR+/HER2-/PIK3CA-wild type(WT)advanced breast cancer(ABC):updated results from the randomized，phase 3 VIKTORIA-1 trial
Gedatolisib（多靶点PI3K/AKT/mTOR[PAM]抑制剂）联合氟维司群±哌柏西利用于HR+/HER2-/PIK3CA野生型（WT）晚期乳腺癌（ABC）患者的二线（2L）治疗：随机、3期VIKTORIA-1研究的更新结果
讲者：Barbara Pistilli，Gustave Roussy，Villejuif，France
摘要号：RF7-05
Capivasertib plus fulvestrant in hormone receptor-positive(HR+)advanced breast cancer(ABC):exploratory ctDNA analyses from the Phase 3 CAPItello-291 trial
Capivasertib联合氟维司群治疗激素受体阳性（HR+）晚期乳腺癌（ABC）：3期CAPItello-291研究的探索性ctDNA分析
讲者：Nicholas C Turner，Royal Marsden Hospital，Institute of Cancer Research，London，United Kingdom
摘要号：RF7-06
Primary results of Ambre，a randomized phase 3comparing mono-chemotherapy(ct)vs abemaciclib+endocrine therapy(et)in hr+/her2-advanced breast cancer(abc)with high visceral tumor burden
Ambre研究主要结果：一项在高内脏肿瘤负荷的HR+/HER2-晚期乳腺癌中比较单药化疗vs阿贝西利联合内分泌治疗的随机III期研究
讲者：Véronique Dieras，Centre Eugène Marquis，Rennes，France
摘要号：RF7-07
Adjuvant Palbociclib for ER+Breast Cancer in the PALLAS Trial(ABCSG-42/AFT-05/PrE0109/BIG-14-13):Post-Recurrence Treatment and Overall Survival
PALLAS研究（ABCSG-42/AFT-05/PrE0109/BIG-14-13）中哌柏西利辅助治疗ER+乳腺癌：复发后治疗与总生存分析
讲者：Angela DeMichele，University of Pennsylvania，Philadelphia，PA
专场：Rapid Fire 4
时间：12月11日4:30 PM–5:30 PM CST
地点：Stars at Night 1-2
摘要号：RF4-01
Central Nervous System Outcomes from the Phase III PATINA Trial(AFT-38)
III期PATINA（AFT-38）研究患者的中枢神经系统结局
讲者：Otto Metzger，Dana-Farber Cancer Institute，Harvard Medical School，Boston，MA
摘要号：RF4-02
Efficacy Analysis of the Randomized Phase III DETECT V trial:Treatment De-escalation by Omission of Chemotherapy and the Effect of Adding Ribociclib in HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer
随机III期DETECT V研究的疗效分析：在HER2+/HR+转移性乳腺癌中省略化疗的降阶梯治疗及联合瑞波西利的效果
讲者：Wolfgang Janni，University Hospital Ulm，Ulm，Germany
摘要号：RF4-03
Evaluation of a whole-exome sequencing tumor-informed circulating tumor DNA MRD assay in patients with early triple-negative breast cancer(TNBC)receiving neoadjuvant chemotherapy(NAC)with or without atezolizumab:A prospective sub study of the NSABP-B59/GBG-96-GeparDouze Trial
在接受新辅助化疗（NAC）（联合或不联合阿替利珠单抗）的早期三阴性乳腺癌（TNBC）患者中，评估基于肿瘤信息的全外显子组测序循环肿瘤DNA MRD检测：NSABP-B59/GBG-96-GeparDouze研究的一项前瞻性亚组研究
讲者：Marija Balic，NSABP Foundation，Inc.;UPMC Hillman Cancer Center;University of Pittsburgh School of Medicine，Pittsburgh，PA
摘要号：RF4-04
Mechanisms of resistance to capivasertib in combination with CDK4/6 inhibitor(CDK4/6i)plus fulvestrant in patients with hormone receptor-positive/HER2-negative(HR+/HER2−)advanced breast cancer(ABC):exploratory analysis from the Phase 1b CAPItello-292 study
在激素受体阳性/HER2阴性（HR+/HER2-）晚期乳腺癌（ABC）患者中，capivasertib联合CDK4/6抑制剂（CDK4/6i）和氟维司群的耐药机制：对1b期CAPItello-292研究的探索性分析
讲者：Dhivya Raja Sudhan，AstraZeneca，Gaithersburg，MD
摘要号：RF4-05
PIK3R1(p85α)alterations define a targetable subset of breast cancer with broad sensitivity to PI3K and AKT inhibitors
PIK3R1（p85α）改变定义了一个对PI3K和AKT抑制剂广泛敏感的可作为治疗靶点的乳腺癌亚群
讲者：Shalinda Fernando，NYU Langone，New York，NY
摘要号：RF4-06
Fdg-pet to assess therapeutic response in patients with bone-dominant metastatic breast cancer，feature:ecog-acrin ea1183
应用FDG-PET评估以骨转移为主的转移性乳腺癌患者的治疗反应：ECOG-ACRIN EA1183研究报告
讲者：Jennifer Marie Specht，University of Washington/Fred Hutch Cancer Center，Seattle，WA
摘要号：RF4-07
Genomic characteristics of de novo HER2-positive metastatic breast cancer
新发HER2阳性转移性乳腺癌的基因组特征
讲者：Shu Yazaki，Memorial Sloan Kettering Cancer Center，New York，NY
京公网安备 11010502033352号